Cardiac drugs. Other cardiac drugs. Tiazotic acid
The active substance of the medicine has anti-ischemic, membrane-stabilising, antioxidant, and immunomodulatory effects. The mechanism of action of the medicine is associated with enhancing the compensatory activation of anaerobic glycolysis and activating oxidising processes in the Krebs cycle while preserving the intracellular ATP pool.
In the complex treatment of coronary heart disease: angina, myocardial infarction, post-infarction cardiosclerosis.
As an adjuvant medication in the therapy of cardiac arrhythmias.
In the complex treatment of chronic hepatitis, alcoholic hepatitis, fibrosis, and hepatic cirrhosis.
In myocardial infarction and unstable angina, the medicine should be administered intravenously slowly at 4 ml of 25 mg/ml solution (100 mg) at a rate of 2 ml/min, or by intravenous drip at a rate of 20–30 drops per minute (4 ml of 25 mg/ml solution should be diluted in 150–250 ml of 0.9 % sodium chloride solution), or by intramuscular administration at 4 ml of 25 mg/ml solution (100 mg) 2–3 times per day. The treatment course is 14 days.